2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Drug shows signs of efficacy in early stage Parkinson’s
A protein called alpha-synuclein builds up in the brains of people with Parkinson’s. This accumulation is believed to play a role in the progressive nature of Parkinson’s.
Dexamethasone for COVID – and perhaps Parkinson’s?
Recent studies screening medical record databases suggest anti-inflammatory drugs like dexamethasone may reduce the risk of developing Parkinson’s.
A biomarker for Parkinson’s?
A research report published this week, highlights a protein that could represent the first ‘biomarker’ for Parkinson’s progression.
The epigenetics of Parkinson’s.
Researchers at the Van Andel Institute in Grand Rapids (Michigan) have identified a “master regulator” gene switch that may protect the brain from neurodegenerative processes associated with Parkinson’s.
DENALI and Biogen team up against LRRK2
The biotech company Denali have announced that they have signed a collaborative deal with the pharmaceutical company Biogen.